Retrospective studies have already suggested that the use of GLP-1 RAs (including semaglutide) as non-insulin adjunct therapies may be effective in improving glucose control and reducing insulin requirements and excess weight in T1D patients [96,97]. This evidence concerns the gene INS and type 1 diabetes mellitus.